Modelling the effect of fibrates on lipoproteins in patients with dyslipidemia

Modelling the effect of fibrates on lipoproteins in patients with dyslipidemia - FIB

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017404

Enrollment

Registered

2020-07-02

Start date

2020-09-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HYPERTRIGLYCERIDMIE E78

Interventions

Group 1: Hypertriglyceridemics, for which fibrates are prescribed to lower their triglycerides. Measurements before the Fibrate and after its adjustment -drawn in the patient-centred care- are used fo

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age = 18 • written consent • Serum TG > 600 mg/dl

Exclusion criteria

Exclusion criteria: 1. serious liver dysfunction (Child-Pugh C) 2. serious kidney dysfunction, with GFR 160 mmHg or diastolic bp > 105 mmHg. 5. alcoholabusus, or abusus of other drugs (but nicotine) 6. Blood-donation within the last 6 weeks prior to the first blood withdrawal 7. Patients with serious acute diseases 8. HbA1c > 8.0% 9. Other serious internistic diseases, associated to the lipid-metabolism 10. hypersensivity to fibrats 11. pregnancy, planned pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Estimation of the lipidfluxes (per Cholesterol ester-Transferprotein (CETP), Lecithin-Cholesterol-Acyltransferase (LCAT) and hepatic lipasis (HL)) in low density lipoproteins (LDL) and high density lipoproteins (HDL). This is done with a mathematical model, based on measurements of triglyzerides, unesterified cholesterol, and cholesterol estern in very low density lipoproteins (VLDL) , intermediate density lipoproteins (IDL), LDL and HDL, as well as Apolipoprotein B-100 (ApoB) in VLDL, IDL, LDL and Apolipoprotein A1 (ApoA1) in HDL.	—

Measure

Time frame

Estimation of the lipidfluxes (per Cholesterol ester-Transferprotein (CETP), Lecithin-Cholesterol-Acyltransferase (LCAT) and hepatic lipasis (HL)) in low density lipoproteins (LDL) and high density lipoproteins (HDL). This is done with a mathematical model, based on measurements of triglyzerides, unesterified cholesterol, and cholesterol estern in very low density lipoproteins (VLDL) , intermediate density lipoproteins (IDL), LDL and HDL, as well as Apolipoprotein B-100 (ApoB) in VLDL, IDL, LDL and Apolipoprotein A1 (ApoA1) in HDL.

—

Secondary

Measure	Time frame
- Concentration of phospholipids in VLDL, IDL, LDL and HDL and concentration of triglyzerides, cholesterpl, Cholesterpl ester, phospholipids in the subfractions of LDL und HDL - ApoB in VLDL, IDL, LDL-1 to LDL-6 and ApoAI in HDL subfractionen 2a, 2b und HDL-3 - HDL-functionality - concentration and distribution of other apolipoproteins in the lipoprotein-subfractions - Activities of the enzyms: phospholipid-transfer-protein (PLTP), lipoprotein-associated phospholipase A2 (Lp-PLA2)	—

Measure

Time frame

- Concentration of phospholipids in VLDL, IDL, LDL and HDL and concentration of triglyzerides, cholesterpl, Cholesterpl ester, phospholipids in the subfractions of LDL und HDL - ApoB in VLDL, IDL, LDL-1 to LDL-6 and ApoAI in HDL subfractionen 2a, 2b und HDL-3 - HDL-functionality - concentration and distribution of other apolipoproteins in the lipoprotein-subfractions - Activities of the enzyms: phospholipid-transfer-protein (PLTP), lipoprotein-associated phospholipase A2 (Lp-PLA2)

—

Countries

Germany

Contacts

Public ContactKarl Winkler

Universitätsklinikum Freiburg Institut für klinische Chemie und Laboratoriumsmedizin

karl.winkler@uniklinik-freiburg.de49 761 27033160

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026